Phase II study of multiple doses of GTx 758 (1800, 3000 or 4500 mg/day) on testosterone levels and pharmacokinetics in male volunteers

Trial Profile

Phase II study of multiple doses of GTx 758 (1800, 3000 or 4500 mg/day) on testosterone levels and pharmacokinetics in male volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2010

At a glance

  • Drugs GTx 758 (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 14 Dec 2010 Results were presented at the Annual Meeting of the Society of Urologic Oncology 2010, according to a GTx media release.
    • 15 Sep 2010 Top-line results have been reported in a GTx media release. Full results from this trial will be presented at upcoming medical meetings.
    • 15 Sep 2010 Status changed from active, no longer recruiting to completed based on results reported in a GTx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top